Skip to main content
Top
Published in: Malaria Journal 1/2012

Open Access 01-10-2012 | Poster presentation

Recognition of Plasmodium falciparum gametocyte surface antigens by plasma antibodies in asymptomatic Ghanaian school children

Authors: Bismarck Dinko, Teun Bousema, Colin J Sutherland

Published in: Malaria Journal | Special Issue 1/2012

Login to get access

Excerpt

Malaria transmission-reducing interventions are key components of malaria control and elimination [1]. However, little is known about the immune responses directed at circulating Plasmodium falciparum gametocytes in humans, knowledge of which would be useful in the development of anti-gametocyte vaccines, which would have the capability to reduce malaria transmission from humans to mosquitoes. In a study in the Gambia, mature gametocyte-infected erythrocytes of P. falciparum were found to carry antigens (gametocyte surface antigens, GSA) that were recognised by malaria patient’s plasma antibodies. These anti-GSA antibodies, taken at a single timepoint, were weakly associated with lower duration of gametocyte carriage in these treated patients [2, 3]. We then sought to determine longitudinal patterns in GSA antibody prevalence and its relationship to possible immune suppression of gametocyte carriage in vivo.
Metadata
Title
Recognition of Plasmodium falciparum gametocyte surface antigens by plasma antibodies in asymptomatic Ghanaian school children
Authors
Bismarck Dinko
Teun Bousema
Colin J Sutherland
Publication date
01-10-2012
Publisher
BioMed Central
Published in
Malaria Journal / Issue Special Issue 1/2012
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-11-S1-P24

Other articles of this Special Issue 1/2012

Malaria Journal 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine